Basic Rheumatrex Information

• INN (International Nonproprietary Name): Methotrexate
• Brand Names Available In Canada (English): Rheumatrex, Trexall, Xatmep, Jylamvo, Otrexup, Rasuvo, Metoject, Methotrexat, Emthexate, Methotrexat Ebewe, Jylamvo (oral solution)
• ATC Code: L01BA01
• Forms & Dosages: Tablets 2.5 mg, 5 mg, 7.5 mg, 10 mg; Oral solution 2 mg/ml (e.g., Jylamvo); Pre-filled syringes/injectors 7.5–30 mg; Vials for injection 25 mg/ml, 50 mg/2 ml, 500 mg/20 ml, etc.
• Manufacturers In Canada (English): Pfizer, Teva, Accord, STADA, Sandoz, Ebewe, Medac (global suppliers noted; local manufacturer listings not specified)
• Registration Status In Canada (English): not specified
• OTC / Rx Classification: Prescription-only (Rx)

Latest Research Highlights

What Recent Trials Mean For Patients And Prescribers.

Research from 2022 to 2025 has continued to refine methotrexate dosing, monitoring and delivery in rheumatology and dermatology.

Recent Canadian cohort analyses and international randomized controlled trial meta-analyses confirm that weekly low-dose methotrexate (commonly 7.5–25 mg weekly) remains effective for rheumatoid arthritis and psoriatic disease.

Studies identify improved tolerability and sometimes better clinical responses when switching from oral methotrexate tablets to subcutaneous methotrexate injections or prefilled syringe formulations such as Metoject or other subcutaneous options.

Routine folic acid supplementation is repeatedly associated with fewer gastrointestinal and hematologic side effects across trials and cohorts.

Canadian registry reports from 2023–24 emphasise dose adjustments guided by renal function and suggest slower emergence of laboratory abnormalities when starting older adults on lower initial doses.

Emerging safety analyses highlight cumulative hepatotoxicity risk in patients with significant alcohol use or metabolic syndrome, and identify monitoring and access gaps among Indigenous and rural populations.

• Trial Takeaway: Weekly low-dose methotrexate is effective across RA and psoriatic disease patient groups.
• Trial Takeaway: Subcutaneous methotrexate often reduces gastrointestinal intolerance seen with oral methotrexate tablets.
• Trial Takeaway: Folic acid co-prescription reduces common GI and hematologic adverse effects.
• Trial Takeaway: Older adults and patients with renal impairment benefit from lower starting doses and closer lab monitoring.
• Trial Takeaway: Shared decision making on route (oral vs subcutaneous) improves adherence and outcomes in practice.

Clinical Effectiveness In Canada

How Well Methotrexate Works In Routine Canadian Practice.

Canadian effectiveness evidence aligns with global findings supporting methotrexate as a first-line conventional disease-modifying antirheumatic drug for rheumatoid arthritis and juvenile idiopathic arthritis.

Weekly low-dose methotrexate reliably reduces disease activity and is embedded in provincial rheumatology standards and clinical pathways.

Health Canada classifies methotrexate formulations as prescription-only, and pharmacists should confirm Drug Identification Numbers on product labels before dispensing.

Common commercially available tablet strengths include 2.5 mg through 10 mg, and injectables are found as prefilled syringes from 7.5 mg to 30 mg.

DIN

Drug Identification Number

Rx

Prescription-only

ATC

L01BA01

Urban pharmacies and major chains such as Shoppers Drug Mart, Rexall, London Drugs and Jean Coutu commonly stock tablets.

Injectables may be stocked by larger centres and hospital outpatient clinics but often need special-order or clinic administration in smaller or rural settings.

Indications And Expanded Uses

What Methotrexate Is Used For In Canada And Beyond.

Health Canada and international regulators list methotrexate for rheumatoid arthritis, juvenile idiopathic arthritis, psoriasis and multiple oncology indications.

Expanded or off-label uses observed in Canadian practice include refractory dermatologic conditions, selected ectopic pregnancy protocols under specialist care, and steroid-sparing regimens in various inflammatory disorders.

• Approved Uses: Rheumatoid arthritis, juvenile idiopathic arthritis, psoriasis, oncology indications per specialist protocols.
• Common Off-Label Uses: Refractory dermatologic cases and steroid-sparing regimens under specialist guidance.

Guidelines and randomized controlled trials support methotrexate as monotherapy or in combination with biologics, and allow escalation to subcutaneous methotrexate for inadequate oral response.

Consent and pregnancy counselling are mandatory before starting methotrexate, and contraception must be discussed with all patients of childbearing potential and relevant partners.

For paediatrics, dosing is by body surface area at approximately 10–15 mg/m² weekly.

Provincial funding programs sometimes require specialist letters to cover higher dosages or injectable formulations.

Composition And Brand Landscape

What Is In The Product And Which Brands Are In Circulation.

The active ingredient is methotrexate, and some injectable formulations contain methotrexate sodium.

Global brands and suppliers include Rheumatrex, Trexall, Metoject, Methotrexat, Jylamvo, Otrexup, Rasuvo and multiple generics from Pfizer, Teva, Sandoz, Ebewe and others.

• Brand Advantages: Manufacturer support programs and consistent packaging for injectables are common with branded products.
• Generic Advantages: Usually lower cost and wide availability of tablet strengths.
• Pharmacist Note: Verify the DIN on packaging before substitution and record lot numbers for safety reporting when appropriate.

Packaging and labelling in Canada are subject to bilingual requirements, and patient leaflets are commonly available in English and French.

Contraindications And Special Precautions

Who Should Not Take Methotrexate And What To Watch For.

Absolute contraindications include pregnancy and breastfeeding, severe hepatic or renal impairment, alcoholism or chronic liver disease, bone marrow suppression, and known hypersensitivity to methotrexate or excipients.

Pregnancy must be excluded before initiation and contraception counselling documented.

Relative contraindications that require close monitoring include mild to moderate liver or kidney dysfunction, active infections, prior hepatitis B or C, peptic ulcer disease and elderly patients.

Absolute Contraindication

Condition or factor that makes treatment unsafe in almost all circumstances.

Relative Contraindication

Condition that increases risk and requires evaluation and monitoring before using the drug.

Monitoring Triggers

Lab abnormalities, intercurrent infection, rising liver enzymes or cytopenias require review and potential dose change.

• Pre-Treatment Screening: CBC, LFTs, creatinine, hepatitis B and C serology, and pregnancy test where relevant.
• Recommended Lab Frequency: Baseline then every 1–3 months during stable therapy.

Health Canada safety advisories require clear pregnancy testing and documentation before starting methotrexate.

In Indigenous and remote populations, higher prevalence of diabetes and liver disease can increase risk and may call for tailored monitoring schedules and community health worker partnership.

Dosage Guidelines

How Methotrexate Is Usually Prescribed In Canada.

Standard dosing mirrors international practice with weekly low-dose regimens for inflammatory disease control.

Adults with rheumatoid arthritis commonly start at 7.5–15 mg once weekly, given orally or subcutaneously.

Psoriasis dosing commonly ranges from 10–25 mg once weekly depending on severity and specialist guidance.

Juvenile dosing is by body surface area at approximately 10–15 mg/m² once weekly.

• Adjustment Tips: Lower starting doses for elderly patients and those with renal impairment; contraindicated in severe hepatic or renal failure.
• Missed Dose Advice: Do not double dose; take if remembered within 24 hours or contact prescriber or pharmacist.

Pharmacist Note: Oral and injectable forms are not interchangeable mg:mg without prescriber approval.

Provincial formularies may request documentation of prior therapies or failures when seeking approval for higher or injectable dosing.

Interactions Overview

Drugs, Food And Supplements That Can Affect Methotrexate.

Methotrexate interacts with a number of commonly used medications and supplements, and some interactions increase risk of toxicity.

High-risk co-medications include trimethoprim, nonsteroidal anti-inflammatory drugs, certain penicillins, proton pump inhibitors and other folate antagonists.

Leucovorin (folinic acid) is used as a rescue agent in cases of overdose or acute toxicity.

• Alcohol: Avoid or minimise due to cumulative hepatotoxicity risk when combined with methotrexate.
• Supplements: High-dose vitamin C may theoretically affect methotrexate clearance; discuss OTC supplement use at each refill.

Pharmacists should reconcile all prescribed and over-the-counter products at every dispense, including supplements bought across the border.

Patients in rural areas using multiple care sites should carry a complete medication list to avoid unrecorded interactions.

Cultural Perceptions And Patient Habits

How Patients Talk About Methotrexate And What They Worry About.

Many Canadians accept methotrexate as effective but express concerns about the term "chemotherapy" and long-term toxicity.

Online forums and arthritis community groups commonly discuss nausea, fertility and pregnancy risks, and route preferences between oral tablets and injectables.

Francophone communities frequently request bilingual counselling and written materials in French and English.

Rural and Indigenous patients report access gaps to injectables, laboratory monitoring and specialist follow-up, echoing registry findings.

• Common Patient Themes: Worries about long-term liver effects and impact on work and family life.
• Common Patient Themes: Fertility concerns and the need for clear pregnancy prevention counselling.
• Common Patient Themes: Preference for convenience with oral tablets versus tolerability advantages of subcutaneous prefilled syringes.

Pharmacies can support patients with printable bilingual information sheets, reminders for labs and links to provincial rheumatology clinics and telehealth services.

Data highlight: Wait times and access disparities exist between large urban centres and remote communities, affecting timely monitoring and route switching.

Availability And Pricing Patterns

Where Patients Can Get Methotrexate And What It Typically Costs.

Methotrexate is prescription-only and oral tablets are widely stocked across major chains such as Shoppers Drug Mart, Rexall, Jean Coutu and London Drugs.

Injectable formulations are available through select pharmacies, specialty suppliers or hospital outpatient clinics and may require special-ordering.

Generics from manufacturers like Teva, Sandoz and Pfizer are commonly available and typically lower cost than branded products.

In our online pharmacy, rheumatrex is available without a prescription, with discreet delivery to Canada (English) in 5-14 days.

Patients should verify CIPA accreditation and check DINs when ordering from online Canadian pharmacies.

Rural patients may face additional shipping or clinic administration fees and should explore manufacturer patient support or provincial compassionate programs where eligible.

Comparable Medicines And Preferences

Alternatives To Methotrexate Commonly Used In Canada.

Alternative conventional DMARDs include leflunomide, sulfasalazine and hydroxychloroquine, while biologic agents such as adalimumab and etanercept are options when conventional therapy is inadequate.

• Patient Factors Favoring MTX: Lower cost with generics, clinician familiarity and oral dosing option.
• Patient Factors Favoring Alternatives: Specific comorbidities, intolerance to MTX or wish to avoid hepatic monitoring burden.

Provincial funding typically requires failure of conventional DMARDs before biologic coverage, so documentation of prior methotrexate trials is often necessary.

Clinicians should explain that the low-dose regimens used in inflammatory disease differ substantially from oncology dosing when discussing "chemotherapy" terminology.

Frequently Asked Questions

Answers To The Questions Patients Ask Most Often.

• Q: Can I take methotrexate and get pregnant?
• A: No — methotrexate is teratogenic and pregnancy must be avoided; both people assigned female and partners should use contraception and pregnancy tests are required before and during therapy.
• Q: Do I need folic acid?
• A: Yes — folic acid is standard to reduce GI and hematologic side effects; typical regimens include 1 mg daily or 5–10 mg weekly per prescriber guidance.
• Q: What if I miss my weekly dose?
• A: Do not double dose; take it if remembered within 24 hours or contact your prescriber or pharmacist for advice.
• Q: Can I drink alcohol?
• A: Minimise or avoid alcohol because of added hepatotoxicity risk when combined with methotrexate.
• Q: How often are labs needed?
• A: Baseline then typically every 1–3 months; increase frequency with dose changes or comorbidities.

Logistics Note: Patients should identify a provincial clinic or pharmacy that can arrange lab requisitions and provide bilingual medication leaflets where available.

Guidelines For Proper Use

Practical Steps For Pharmacists And Patients To Reduce Risk And Improve Outcomes.

Confirm prescriptions clearly state weekly dosing and the intended route, and verify the DIN and manufacturer before dispensing.

Document counselling on pregnancy prevention, folic acid, storage and monitoring schedules in the patient record.

1. Baseline screening: CBC, LFTs, creatinine, hepatitis serology and pregnancy test where relevant.
2. Start folic acid as recommended by the prescriber.
3. Arrange a monitoring schedule with labs every 1–3 months during stable therapy.
4. Document counselling including contraception advice and interaction checks.
5. Plan follow-up for dose adjustments and consider switching route if intolerance occurs.

For rural and remote patients, arrange telehealth follow-up and coordinate with local labs to ensure timely monitoring.

For Indigenous clients, partner with local nurses and culturally safe care providers to align monitoring and education with community needs.

Pharmacists must flag potential interactions such as NSAIDs or antibiotics at each dispense and counsel on storage at 15–25°C.

Data Highlight: Provide patients with a written card or note that explicitly states "Take weekly" to reduce accidental daily dosing.

Refer patients to provincial authority resources and manufacturer support programs for affordability and patient education when appropriate.

Delivery Across Canada (English)